Oncogenic alternative splicing switches: Role in cancer progression and prospects for therapy

International Journal of Cell Biology

Volumn , Issue , 2013, Pages

  Bonomi, Serena ^a   Gallo, Stefania ^a   Catillo, Morena ^a   Pignataro, Daniela ^a   Biamonti, Giuseppe ^a   Ghigna, Claudia ^a  

^a CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CELL ADHESION MOLECULE; CORTACTIN; FAM3B PROTEIN; HERMES ANTIGEN; KRUPPEL LIKE FACTOR 6; MENA PROTEIN; MONOCLONAL ANTIBODY; NERVE CELL ADHESION MOLECULE L1; ONCOPROTEIN; RAC1 PROTEIN; RNA ISOFORM; RON PROTEIN; SVEP1 PROTEIN; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CARCINOGENESIS; GENE SWITCHING; GENETIC VARIABILITY; HUMAN; HYPOXIA; MALIGNANT TRANSFORMATION; METASTASIS; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; RNA TRANSLATION; TUMOR INVASION; TUMOR SUPPRESSOR GENE;

EID: 84888879760     PISSN: 16878876     EISSN: 16878884     Source Type: Journal    
DOI: 10.1155/2013/962038     Document Type: Review

References (197)

1. Early P., Rogers J., Davis M., Two mRNAs can be produced from a single immunoglobulin gene by alternative RNA processing pathways. Cell 1980 20 2 313 319 2-s2.0-0018896724 (Pubitemid 10117747)
2. Alt F. W., Bothwell A. L. M., Knapp M., Synthesis of secreted and membrane-bound immunoglobulin Mu heavy chains is directed by mRNAs that differ at their 3' ends. Cell 1980 20 2 293 301 2-s2.0-0018848546 (Pubitemid 10117745)
3. Wang E. T., Sandberg R., Luo S., Khrebtukova I., Zhang L., Mayr C., Kingsmore S. F., Schroth G. P., Burge C. B., Alternative isoform regulation in human tissue transcriptomes. Nature 2008 456 7221 470 476 2-s2.0-56549101959 10.1038/nature07509 (Pubitemid 352759009)
4. Pan Q., Shai O., Lee L. J., Frey B. J., Blencowe B. J., Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nature Genetics 2008 40 12 1413 1415 2-s2.0-56749098074 10.1038/ng.259
5. Ghigna C., Valacca C., Biamonti G., Alternative splicing and tumor progression. Current Genomics 2008 9 8 556 570 2-s2.0-66049085709 10.2174/138920208786847971
6. Nilsen T. W., Graveley B. R., Expansion of the eukaryotic proteome by alternative splicing. Nature 2010 463 7280 457 463 2-s2.0-75849145292 10.1038/nature08909
7. Licatalosi D. D., Darnell R. B., RNA processing and its regulation: global insights into biological networks. Nature Reviews Genetics 2010 11 1 75 87 2-s2.0-72849106592 10.1038/nrg2673
8. Braunschweig U., Gueroussov S., Plocik A. M., Graveley B. R., Blencowe B. J., Dynamic integration of splicing within gene regulatory pathways. Cell 2013 152 6 1252 1269
9. David C. J., Manley J. L., Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged. Genes and Development 2010 24 21 2343 2364 2-s2.0-78049416081 10.1101/gad.1973010
10. Biamonti G., Bonomi S., Gallo S., Ghigna C., Making alternative splicing decisions during epithelial-to-mesenchymal transition (EMT). Cellular and Molecular Life Sciences 2012 69 15 2515 2526 2-s2.0-84857026190 10.1007/s00018-012-0931-7
11. He C., Zhou F., Zuo Z., Cheng H., Zhou R., A global view of cancer-specific transcript variants by subtractive transcriptome-wide analysis. PLoS ONE 2009 4 3 2-s2.0-62749098351 10.1371/journal.pone.0004732 e4732
12. Jewer M., Findlay S. D., Postovit L., Post-transcriptional regulation in cancer progression: microenvironmental control of alternative splicing and translation. Journal of Cell Communication and Signaling 2012 6 4 233 248
13. Hanahan D., Weinberg R. A., Hallmarks of cancer: the next generation. Cell 2011 144 5 646 674 2-s2.0-79952284127 10.1016/j.cell.2011.02.013
14. Hanahan D., Weinberg R. A., The hallmarks of cancer. Cell 2000 100 1 57 70 2-s2.0-0034614637 10.1016/S0092-8674(00)81683-9 (Pubitemid 30046295)
15. Vaupel P., The role of hypoxia-induced factors in tumor progression. Oncologist 2004 9 5 10 17 2-s2.0-10644234769 (Pubitemid 39658341)
16. Lorusso G., Rüegg C., The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochemistry and Cell Biology 2008 130 6 1091 1103 2-s2.0-56749107194 10.1007/s00418-008-0530-8
17. Gatenby R. A., Gawlinski E. T., Gmitro A. F., Kaylor B., Gillies R. J., Acid-mediated tumor invasion: a multidisciplinary study. Cancer Research 2006 66 10 5216 5223 2-s2.0-33744942376 10.1158/0008-5472.CAN-05-4193 (Pubitemid 43844945)
18. Cairns R., Papandreou I., Denko N., Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Molecular Cancer Research 2006 4 2 61 70 2-s2.0-33645123894 10.1158/1541-7786.MCR-06-0002
19. Semenza G. L., Targeting HIF-1 for cancer therapy. Nature Reviews Cancer 2003 3 10 721 732 2-s2.0-0142166332 (Pubitemid 37328811)
20. Forristal C. E., Wright K. L., Hanley N. A., Oreffo R. O. C., Houghton F. D., Hypoxia inducible factors regulate pluripotency and proliferation in human embryonic stem cells cultured at reduced oxygen tensions. Reproduction 2010 139 1 85 97 2-s2.0-75149117810 10.1530/REP-09-0300
21. Erler J. T., Bennewith K. L., Nicolau M., Dornhöfer N., Kong C., Le Q.-T., Chi J.-T. A., Jeffrey S. S., Giaccia A. J., Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006 440 7088 1222 1226 2-s2.0-33646365644 10.1038/nature04695
22. Gerhardt H., VEGF and endothelial guidance in angiogenic sprouting. Organogenesis 2008 4 4 241 246 2-s2.0-57349200481
23. Potente M., Gerhardt H., Carmeliet P., Basic and therapeutic aspects of angiogenesis. Cell 2011 146 6 873 887 2-s2.0-80052933197 10.1016/j.cell.2011.08. 039
24. Finley S. D., Popel A. S., Predicting the effects of anti-angiogenic agents targeting specific VEGF isoforms. BMC Biology 2012 14 3 500 509 2-s2.0-84860547530 10.1208/s12248-012-9363-4
25. Qiu Y., Hoareau-Aveilla C., Oltean S., Harper S. J., Bates D. O., The anti-angiogenic isoforms of VEGF in health and disease. Biochemical Society Transactions 2009 37 6 1207 1213 2-s2.0-70450203391 10.1042/BST0371207
26. Hilmi C., Guyot M., Pagès G., VEGF spliced variants: possible role of anti-angiogenesis therapy. Journal of Nucleic Acids 2012 2012 7 162692 10.1155/2012/162692
27. Nowak D. G., Woolard J., Amin E. M., Konopatskaya O., Saleem M. A., Churchill A. J., Ladomery M. R., Harper S. J., Bates D. O., Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors. Journal of Cell Science 2008 121 20 3487 3495 2-s2.0-56349136033 10.1242/jcs.016410
28. Karni R., De Stanchina E., Lowe S. W., Sinha R., Mu D., Krainer A. R., The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nature Structural and Molecular Biology 2007 14 3 185 193 2-s2.0-33847630730 10.1038/nsmb1209 (Pubitemid 46355578)
29. Cohen-Eliav M., Golan-Gerstl R., Siegfried Z., Andersen C. L., Thorsen K., Ørntoft T. F., Mu D., Karni R., The splicing factor SRSF6 is amplified and is an oncoprotein in lung and colon cancers. The Journal of Pathology 2013 229 4 630 639
30. Nowak D. G., Amin E. M., Rennel E. S., Hoareau-Aveilla C., Gammons M., Damodoran G., Hagiwara M., Harper S. J., Woolard J., Ladomery M. R., Bates D. O., Regulation of Vascular Endothelial Growth Factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis. Journal of Biological Chemistry 2010 285 8 5532 5540 2-s2.0-77949318969 10.1074/jbc.M109.074930
31. Hayes G. M., Carrigan P. E., Miller L. J., Serine-arginine protein kinase 1 overexpression is associated with tumorigenic imbalance in mitogen-activated protein kinase pathways in breast, colonic, and pancreatic carcinomas. Cancer Research 2007 67 5 2072 2080 2-s2.0-33947223157 10.1158/0008-5472.CAN-06-2969 (Pubitemid 46424225)
32. Weigand J. E., Boeckel J., Gellert P., Dimmeler S., Hypoxia-induced alternative splicing in endothelial cells. PLoS ONE 2012 7 8 e42697
33. Moller-Levet C. S., Betts G. N. J., Harris A. L., Homer J. J., West C. M. L., Miller C. J., Exon array analysis of head and neck cancers identifies a hypoxia related splice variant of LAMA3 associated with a poor prognosis. PLoS Computational Biology 2009 5 11 2-s2.0-73449118582 10.1371/journal.pcbi.1000571 e1000571
34. Marinkovich M. P., Tumour microenvironment: laminin 332 in squamous-cell carcinoma. Nature Reviews Cancer 2007 7 5 370 380 2-s2.0-34247474890 10.1038/nrc2089 (Pubitemid 46652480)
35. Maynard M. A., Qi H., Chung J., Lee E. H. L., Kondo Y., Hara S., Conaway R. C., Conaway J. W., Ohh M., Multiple splice variants of the human HIF-3 α locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. Journal of Biological Chemistry 2003 278 13 11032 11040 2-s2.0-0037837724 10.1074/jbc.M208681200 (Pubitemid 36792653)
36. Ando H., Natsume A., Iwami K., Ohka F., Kuchimaru T., Kizaka-Kondoh S., Ito K., Saito K., Sugita S., A hypoxia-inducible factor (HIF)-3 α splicing variant, HIF-3 α 4 impairs angiogenesis in hypervascular malignant meningiomas with epigenetically silenced HIF-3 α 4. Biochemical and Biophysical Research Communications 2013 433 1 139 144
37. Menéndez J. A., Mehmi I., Griggs D. W., Lupu R., The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives. Endocrine-Related Cancer 2003 10 2 141 152 2-s2.0-0038274849 10.1677/erc.0.0100141 (Pubitemid 36758643)
38. Xie D., Yin D., Wang H.-J., Liu G.-T., Elashoff R., Black K., Koeffler H. P., Levels of expression of CYR61 and CTGF are prognostic for tumor progression and survival of individuals with gliomas. Clinical Cancer Research 2004 10 6 2072 2081 2-s2.0-1642350329 10.1158/1078-0432.CCR-0659-03 (Pubitemid 38375569)
39. Bleau A.-M., Planque N., Perbal B., CCN proteins and cancer: two to tango. Frontiers in Bioscience 2005 10 998 1009 2-s2.0-33645231002
40. Hirschfeld M., Hausen A. Z., Bettendorf H., Jäger M., Stickeier E., Alternative splicing of Cyr61 Is regulated by hypoxia and significantly changed in breast cancer. Cancer Research 2009 69 5 2082 2090 2-s2.0-62449084935 10.1158/0008-5472.CAN-08-1997
41. Naor D., Nedvetzki S., Golan I., Melnik L., Faitelson Y., CD44 in cancer. Critical Reviews in Clinical Laboratory Sciences 2002 39 6 527 579 2-s2.0-0036445586 10.1080/10408360290795574 (Pubitemid 35425379)
42. Ponta H., Sherman L., Herrlich P. A., CD44: from adhesion molecules to signalling regulators. Nature Reviews Molecular Cell Biology 2003 4 1 33 45 2-s2.0-0037227965 10.1038/nrm1004 (Pubitemid 36077255)
43. Orian-Rousseau V., CD44, a therapeutic target for metastasising tumours. European Journal of Cancer 2010 46 7 1271 1277 2-s2.0-77950561915 10.1016/j.ejca.2010.02.024
44. Klingbeil P., Natrajan R., Everitt G., Vatcheva R., Marchio C., Palacios J., Buerger H., Reis-Filho J. S., Isacke C. M., CD44 is overexpressed in basal-like breast cancers but is not a driver of 11p13 amplification. Breast Cancer Research and Treatment 2010 120 1 95 109 2-s2.0-74849140955 10.1007/s10549-009-0380-7
45. Auvinen P., Tammi R., Tammi M., Johansson R., Kosma V.-M., Expression of CD44s, CD44v3 and CD44v6 in benign and malignant breast lesions: correlation and colocalization with hyaluronan. Histopathology 2005 47 4 420 428 2-s2.0-26444490562 10.1111/j.1365-2559.2005.02220.x (Pubitemid 41428491)
46. Saito S., Okabe H., Watanabe M., Ishimoto T., Iwatsuki M., Baba Y., Tanaka Y., Kurashige J., Miyamoto Y., CD44v6 expression is related to mesenchymal phenotype and poor prognosis in patients with colorectal cancer. Oncology Reports 2013 29 4 1570 1578
47. Kopp R., Fichter M., Schalhorn G., Danescu J., Classen S., Frequent expression of the high molecular, 673-bp CD44v3,v8-10 variant in colorectal adenomas and carcinomas. International Journal of Molecular Medicine 2009 24 5 677 683 2-s2.0-70350752040 10.3892/ijmm-00000279
48. Krishnamachary B., Penet M., Nimmagadda S., Mironchik Y., Raman V., Solaiyappan M., Semenza G. L., Pomper M. G., Bhujwalla Z. M., Hypoxia regulates CD44 and its variant isoforms through HIF-1 α in triple negative breast cancer. PLoS ONE 2012 7 8 e44078
49. Hirschfeld M., Zhang B., Jaeger M., Stamm S., Erbes T., Mayer S., Tong X., Stickeler E., Hypoxia-dependent mRNA expression pattern of splicing factor YT521 and its impact on oncological important target gene expression. Molecular Carcinogenesis 2013 10.1002/mc.22045
50. Zhang B., Hausen A. Z., Orlowska-Volk M., Jäger M., Bettendorf H., Stamm S., Hirschfeld M., Yiqin O., Tong X., Gitsch G., Stickeler E., Alternative splicing-related factor YT521: an independent prognostic factor in endometrial cancer. International Journal of Gynecological Cancer 2010 20 4 492 499 2-s2.0-77952271631 10.1111/IGC.0b013e3181d66ffe
51. Jeyaraj S. C., O'Brien D. M., Chandler D. S., MDM2 and MDM4 splicing: an integral part of the cancer spliceome. Frontiers in Bioscience 2009 14 7 2647 2656 2-s2.0-63849157552 10.2741/3402
52. García Pedrero J. M., Zuazua P., Martínez-Campa C., Lazo P. S., Ramos S., The naturally occurring variant of estrogen receptor (ER) ERΔE7 suppresses estrogen-dependent transcriptional activation by both wild-type ER α and ER β Endocrinology 2003 144 7 2967 2976 2-s2.0-0038675231 10.1210/en.2002-0027 (Pubitemid 36819899)
53. Farrugia D. J., Agarwal M. K., Pankratz V. S., Deffenbaugh A. M., Pruss D., Frye C., Wadum L., Johnson K., Mentlick J., Tavtigian S. V., Goldgar D. E., Couch F. J., Functional assays for classification of BRCA2 variants of uncertain significance. Cancer Research 2008 68 9 3523 3531 2-s2.0-44849102450 10.1158/0008-5472.CAN-07-1587
54. Matsuyama M., Chijiwa T., Inoue Y., Abe Y., Nishi M., Miyazaki N., Furukawa D., Mukai M., Suemizu H., Sekido Y., Ueyama Y., Nakamura M., Alternative splicing variant of vascular endothelial growth factor-A is a critical prognostic factor in non-small cell lung cancer. Oncology Reports 2009 22 6 1407 1413 2-s2.0-70449350663 10.3892/or-00000582
55. Cork D. M. W., Lennard T. W. J., Tyson-Capper A. J., Alternative splicing and the progesterone receptor in breast cancer. Breast Cancer Research 2008 10 3, article 207 2-s2.0-55749105893 10.1186/bcr2097
56. Valastyan S., Weinberg R. A., Tumor metastasis: molecular insights and evolving paradigms. Cell 2011 147 2 275 292 2-s2.0-80054686286 10.1016/j.cell.2011.09.024
57. De Craene B., Berx G., Regulatory networks defining EMT during cancer initiation and progression. Nature Reviews 2013 13 2 97 110
58. Lim J., Thiery J. P., Epithelial-mesenchymal transitions: insights from development. Development 2012 139 19 3471 3486
59. Polyak K., Weinberg R. A., Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nature Reviews Cancer 2009 9 4 265 273 2-s2.0-63049123066 10.1038/nrc2620
60. Thiery J. P., Acloque H., Huang R. Y. J., Nieto M. A., Epithelial-mesenchymal transitions in development and disease. Cell 2009 139 5 871 890 2-s2.0-70450198396 10.1016/j.cell.2009.11.007
61. Bullock M. D., Sayan A. E., Packham G. K., Mirnezami A. H., MicroRNAs: critical regulators of epithelial to mesenchymal (EMT) and mesenchymal to epithelial transition (MET) in cancer progression. Biology of the Cell/Under the Auspices of the European Cell Biology Organization 2012 104 1 3 12
62. Wu C., Tsai Y., Wu M., Teng S., Wu K., Epigenetic reprogramming and post-transcriptional regulation during the epithelial-mesenchymal transition. Trends in Genetics 2012 28 9 454 463
63. Zhou Y.-Q., He C., Chen Y.-Q., Wang D., Wang M.-H., Altered expression of the RON receptor tyrosine kinase in primary human colorectal adenocarcinomas: generation of different splicing RON variants and their oncogenic potential. Oncogene 2003 22 2 186 197 2-s2.0-0037448657 10.1038/sj.onc.1206075 (Pubitemid 36174176)
64. Ghigna C., Giordano S., Shen H., Benvenuto F., Castiglioni F., Comoglio P. M., Green M. R., Riva S., Biamonti G., Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Molecular Cell 2005 20 6 881 890 2-s2.0-29144447982 10.1016/j.molcel.2005.10.026 (Pubitemid 41814877)
65. Valacca C., Bonomi S., Buratti E., Pedrotti S., Baralle F. E., Sette C., Ghigna C., Biamonti G., Sam68 regulates EMT through alternative splicing-activated nonsense-mediated mRNA decay of the SF2/ASF proto-oncogene. Journal of Cell Biology 2010 191 1 87 99 2-s2.0-77957726684 10.1083/jcb. 201001073
66. Bielli P., Busà R., Paronetto M. P., Sette C., The RNA-binding protein Sam68 is a multifunctional player in human cancer. Endocrine-Related Cancer 2011 18 4 R91 R102 2-s2.0-80051951015 10.1530/ERC-11-0041
67. Lukong K. E., Richard S., Sam68, the KH domain-containing superSTAR. Biochimica et Biophysica Acta 2003 1653 2 73 86 2-s2.0-0344391998 10.1016/j.bbcan.2003.09.001 (Pubitemid 37487649)
68. Brignatz C., Paronetto M. P., Opi S., Cappellari M., Audebert S., Feuillet V., Bismuth G., Roche S., Arold S. T., Sette C., Collette Y., Alternative splicing modulates autoinhibition and SH3 accessibility in the Src kinase Fyn. Molecular and Cellular Biology 2009 29 24 6438 6448 2-s2.0-71949096690 10.1128/MCB.00398-09
69. Lukong K. E., Larocque D., Tyner A. L., Richard S., Tyrosine phosphorylation of Sam68 by breast tumor kinase regulates intranuclear localization and cell cycle progression. Journal of Biological Chemistry 2005 280 46 38639 38647 2-s2.0-33644663231 10.1074/jbc.M505802200 (Pubitemid 43853766)
70. Matter N., Herrlich P., König H., Signal-dependent regulation of splicing via phosphorylation of Sam68. Nature 2002 420 6916 691 695 2-s2.0-0037069651 10.1038/nature01153 (Pubitemid 36764503)
71. Egeblad M., Werb Z., New functions for the matrix metalloproteinases in cancer progression. Nature Reviews Cancer 2002 2 3 161 174 2-s2.0-0036512208 (Pubitemid 37328786)
72. Stallings-Mann M. L., Waldmann J., Zhang Y., Miller E., Gauthier M. L., Visscher D. W., Downey G. P., Radisky E. S., Fields A. P., Matrix metalloproteinase induction of Rac1b, a key effector of lung cancer progression. Science Translational Medicine 2012 4 142 142ra95
73. Radisky D. C., Levy D. D., Littlepage L. E., Liu H., Nelson C. M., Fata J. E., Leake D., Godden E. L., Albertson D. G., Nieto M. A., Werb Z., Bissell M. J., Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 2005 436 7047 123 127 2-s2.0-21844432918 10.1038/nature03688 (Pubitemid 40966197)
74. Bosco E. E., Mulloy J. C., Zheng Y., Rac1 GTPase: a "Rac" of all trades. Cellular and Molecular Life Sciences 2009 66 3 370 374 2-s2.0-59349105526 10.1007/s00018-008-8552-x
75. Jordan P., Brazão R., Boavida M. G., Gespach C., Chastre E., Cloning of a novel human Rac1b splice variant with increased expression in colorectal tumors. Oncogene 1999 18 48 6835 6839 2-s2.0-0033581944
76. Schnelzer A., Prechtel D., Knaus U., Dehne K., Gerhard M., Graeff H., Harbeck N., Schmitt M., Lengyel E., Rac1 in human breast cancer: overexpression, mutation analysis, and characterization of a new isoform, Rac1b. Oncogene 2000 19 26 3013 3020 2-s2.0-0034659739 (Pubitemid 30389092)
77. McConnell B. B., Yang V. W., Mammalian Krüppel-Like factors in health and diseases. Physiological Reviews 2010 90 4 1337 1381 2-s2.0-78149481592 10.1152/physrev.00058.2009
78. Hatami R., Sieuwerts A. M., Izadmehr S., Yao Z., Qiao R. F., Papa L., Look M. P., Smid M., Ohlssen J., KLF6-SV1 drives breast cancer metastasis and is associated with poor survival. Science Translational Medicine 2013 5 169 169ra12
79. Narla G., DiFeo A., Fernandez Y., Dhanasekaran S., Huang F., Sangodkar J., Hod E., Leake D., Friedman S. L., Hall S. J., Chinnaiyan A. M., Gerald W. L., Rubin M. A., Martignetti J. A., KLF6-SV1 overexpression accelerates human and mouse prostate cancer progression and metastasis. Journal of Clinical Investigation 2008 118 8 2711 2721 2-s2.0-48749088691 10.1172/JCI34780
80. Narla G., Difeo A., Yao S., Banno A., Hod E., Reeves H. L., Qiao R. F., Camacho-Vanegas O., Levine A., Kirschenbaum A., Chan A. M., Friedman S. L., Martignetti J. A., Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread. Cancer Research 2005 65 13 5761 5768 2-s2.0-21344473196 10.1158/0008-5472.CAN-05-0217 (Pubitemid 40911179)
81. DiFeo A., Narla G., Hirshfeld J., Camacho-Vanegas O., Narla J., Rose S. L., Kalir T., Yao S., Levine A., Birrer M. J., Bonome T., Friedman S. L., Buller R. E., Martignetti J. A., Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination. Clinical Cancer Research 2006 12 12 3730 3739 2-s2.0-33745725772 10.1158/1078-0432.CCR-06-0054 (Pubitemid 44000254)
82. DiFeo A., Martignetti J. A., Narla G., The role of KLF6 and its splice variants in cancer therapy. Drug Resistance Updates 2009 12 1-2 1 7 2-s2.0-62949123360 10.1016/j.drup.2008.11.001
83. Zhu Y., Xu G., Patel A., McLaughlin M. M., Silverman C., Knecht K. A., Sweitzer S., Li X., McDonnell P., Mirabile R., Zimmerman D., Boyce R., Tierney L. A., Hu E., Livi G. P., Wolf B. A., Abdel-Meguid S. S., Rose G. D., Aurora R., Hensley P., Briggs M., Young P. R., Cloning, expression, and initial characterization of a novel cytokine-like gene family. Genomics 2002 80 2 144 150 2-s2.0-0036989990 10.1006/geno.2002.6816 (Pubitemid 36197956)
84. Li Z., Mou H., Wang T., Xue J., Deng B., Qian L., Zhou Y., Gong W., Wang J. M., A non-secretory form of FAM3B promotes invasion and metastasis of human colon cancer cells by upregulating Slug expression. Cancer Letters 2013 328 2 278 284
85. Robert-Cooperman C. E., Carnegie J. R., Wilson C. G., Yang J., Cook J. R., Wu J., Young R. A., Wolf B. A., Burkhardt B. R., Targeted disruption of pancreatic-derived factor (PANDER, FAM3B) impairs pancreatic β -cell function. Diabetes 2010 59 9 2209 2218 2-s2.0-77956387230 10.2337/db09-1552
86. Carnegie J. R., Robert-Cooperman C. E., Wu J., Young R. A., Wolf B. A., Burkhardt B. R., Characterization of the expression, localization, and secretion of PANDER in α -cells. Molecular and Cellular Endocrinology 2010 325 1-2 36 45 2-s2.0-77954387145 10.1016/j.mce.2010.05.008
87. Huang H.-L., Wu B.-Y., Yang S.-B., Shao Y., You W.-D., Wang W.-H., Wang M.-W., Down-regulation of PANDER mRNA in gastric cancer. World Chinese Journal of Digestology 2008 16 14 1513 1518 2-s2.0-49149088676
88. Ridley A. J., Life at the leading edge. Cell 2011 145 7 1012 1022 2-s2.0-79959677602 10.1016/j.cell.2011.06.010
89. Yilmaz M., Christofori G., EMT, the cytoskeleton, and cancer cell invasion. Cancer and Metastasis Reviews 2009 28 1-2 15 33 2-s2.0-65349132693 10.1007/s10555-008-9169-0
90. Gligorijevic B., Wyckoff J., Yamaguchi H., Wang Y., Roussos E. T., Condeelis J., N-WASP-mediated invadopodium formation is involved in intravasation and lung metastasis of mammary tumors. Journal of Cell Science 2012 125 3 724 734 2-s2.0-84858120190 10.1242/jcs.092726
91. Eckert M. A., Lwin T. M., Chang A. T., Kim J., Danis E., Ohno-Machado L., Yang J., Twist1-induced invadopodia formation promotes tumor metastasis. Cancer Cell 2011 19 3 372 386 2-s2.0-79952499030 10.1016/j.ccr.2011.01.036
92. Oser M., Yamaguchi H., Mader C. C., Bravo-Cordero J. J., Arias M., Chen X., DesMarais V., Van Rheenen J., Koleske A. J., Condeelis J., Cortactin regulates cofilin and N-WASp activities to control the stages of invadopodium assembly and maturation. Journal of Cell Biology 2009 186 4 571 587 2-s2.0-69449096397 10.1083/jcb.200812176
93. Buccione R., Caldieri G., Ayala I., Invadopodia: specialized tumor cell structures for the focal degradation of the extracellular matrix. Cancer and Metastasis Reviews 2009 28 1-2 137 149 2-s2.0-68549107801 10.1007/s10555-008- 9176-1
94. Mader C. C., Oser M., Magalhaes M. A. O., Bravo-Cordero J. J., Condeelis J., Koleske A. J., Gil-Henn H., An EGFR-Src-Arg-cortactin pathway mediates functional maturation of invadopodia and breast cancer cell invasion. Cancer Research 2011 71 5 1730 1741 2-s2.0-79952203229 10.1158/0008-5472.CAN-10-1432
95. Van Rossum A. G. S. H., De Graaf J. H., Schuuring-Scholtes E., Kluin P. M., Fan Y.-X., Zhan X., Moolenaar W. H., Schuuring E., Alternative splicing of the actin binding domain of human cortactin affects cell migration. Journal of Biological Chemistry 2003 278 46 45672 45679 2-s2.0-0242580785 10.1074/jbc.M306688200 (Pubitemid 37432709)
96. Liu Y., Conaway L., Rutherford Bethard J., Al-Ayoubi A. M., Thompson Bradley A., Zheng H., Weed S. A., Eblen S. T., Phosphorylation of the alternative mRNA splicing factor 45 (SPF45) by Clk1 regulates its splice site utilization, cell migration and invasion. Nucleic Acids Research 2013 41 9 4949 4962 10.1093/nar/gkt170
97. Al-Ayoubi A. M., Zheng H., Liu Y., Bai T., Eblen S. T., Mitogen-activated protein kinase phosphorylation of splicing factor 45 (SPF45) regulates SPF45 alternative splicing site utilization, proliferation, and cell adhesion. Molecular and Cellular Biology 2012 32 14 2880 2893
98. Corsini L., Bonna S., Basquin J., Hothorn M., Scheffzek K., Valcárcel J., Sattler M., U2AF-homology motif interactions are required for alternative splicing regulation by SPF45. Nature Structural & Molecular Biology 2007 14 7 620 629 2-s2.0-34548600067 10.1038/nsmb1260 (Pubitemid 47037067)
99. Martinez-Quiles N., Ho H.-Y. H., Kirschner M. W., Ramesh N., Geha R. S., Erk/Src phosphorylation of cortactin acts as a switch on-switch off mechanism that controls its ability to activate N-WASP. Molecular and Cellular Biology 2004 24 12 5269 5280 2-s2.0-2942594602 10.1128/MCB.24.12.5269-5280.2004 (Pubitemid 38738162)
100. Di Modugno F., Mottolese M., Di Benedetto A., Conidi A., Novelli F., Perracchio L., Venturo I., Botti C., Jager E., Santoni A., Natali P. G., Nisticò P., The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors. Clinical Cancer Research 2006 12 5 1470 1478 2-s2.0-33645048173 10.1158/1078-0432.CCR-05-2027
101. + T-cell immune response. International Journal of Cancer 2004 109 6 909 918 2-s2.0-9244236729 10.1002/ijc.20094 (Pubitemid 38500748)
102. Di Modugno F., DeMonte L., Balsamo M., Bronzi G., Nicotra M. R., Alessio M., Jager E., Condeelis J. S., Santoni A., Natali P. G., Nisticò P., Molecular cloning of hMena (ENAH) and its splice variant hMena +11a: epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines. Cancer Research 2007 67 6 2657 2665 2-s2.0-34047257715 10.1158/0008-5472.CAN-06-1997 (Pubitemid 46548953)
103. Goswami S., Philippar U., Sun D., Patsialou A., Avraham J., Wang W., Di Modugno F., Nistico P., Gertler F. B., Condeelis J. S., Identification of invasion specific splice variants of the cytoskeletal protein Mena present in mammary tumor cells during invasion in vivo. Clinical and Experimental Metastasis 2009 26 2 153 159 2-s2.0-60449117235 10.1007/s10585-008-9225-8
104. Di Modugno F., Iapicca P., Boudreau A., Mottolese M., Terrenato I., Perracchio L., Carstens R. P., Santoni A., Bissell M. J., Splicing program of human MENA produces a previously undescribed isoform associated with invasive, mesenchymal-like breast tumors. Proceedings of the National Academy of Sciences of the United States of America 2012 109 47 19280 19285
105. Philippar U., Roussos E. T., Oser M., Yamaguchi H., Kim H.-D., Giampieri S., Wang Y., Goswami S., Wyckoff J. B., Lauffenburger D. A., Sahai E., Condeelis J. S., Gertler F. B., A Mena invasion isoform potentiates EGF-induced carcinoma cell invasion and metastasis. Developmental Cell 2008 15 6 813 828 2-s2.0-57049125131 10.1016/j.devcel.2008.09.003
106. Roussos E. T., Balsamo M., Alford S. K., Wyckoff J. B., Gligorijevic B., Wang Y., Pozzuto M., Stobezki R., Goswami S., Segall J. E., Lauffenburger D. A., Bresnick A. R., Gertler F. B., Condeelis J. S., Mena invasive (MenaINV) promotes multicellular streaming motility and transendothelial migration in a mouse model of breast cancer. Journal of Cell Science 2011 124 13 2120 2131 2-s2.0-79960303574 10.1242/jcs.086231
107. Warzecha C. C., Carstens R. P., Complex changes in alternative pre-mRNA splicing play a central role in the epithelial-to-mesenchymal transition (EMT). Seminars in Cancer Biology 2012 22 5-6 417 427 2-s2.0-84860594334 10.1016/j.semcancer.2012.04.003
108. Warzecha C. C., Jiang P., Amirikian K., Dittmar K. A., Lu H., Shen S., Guo W., Xing Y., Carstens R. P., An ESRP-regulated splicing programme is abrogated during the epithelial-mesenchymal transition. EMBO Journal 2010 29 19 3286 3300 2-s2.0-77957767273 10.1038/emboj.2010.195
109. Warzecha C. C., Shen S., Xing Y., Carstens R. P., The epithelial splicing factors ESRP1 and ESRP2 positively and negatively regulate diverse types of alternative splicing events. RNA Biology 2009 6 5 546 562 2-s2.0-77950552549
110. Björklund M., Koivunen E., Gelatinase-mediated migration and invasion of cancer cells. Biochimica et Biophysica Acta 2005 1755 1 37 69 2-s2.0-19344366798 10.1016/j.bbcan.2005.03.001 (Pubitemid 40720240)
111. Hauser S., Bickel L., Weinspach D., Gerg M., Schäfer M. K., Pfeifer M., Hazin J., Schelter F., Weidle U. H., Ramser J., Volkmann J., Meindl A., Schmitt M., Schrötzlmair F., Altevogt P., Krüger A., Full-length L1CAM and not its δ 2 δ 27 splice variant promotes metastasis through induction of gelatinase expression. PLoS ONE 2011 6 4 2-s2.0-79955551591 10.1371/journal.pone.0018989 e18989
112. Talmadge J. E., Fidler I. J., AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Research 2010 70 14 5649 5669 2-s2.0-77955015464 10.1158/0008-5472.CAN-10-1040
113. Shur I., Zemer-Tov E., Socher R., Benayahu D., SVEP1 expression is regulated in estrogen-dependent manner. Journal of Cellular Physiology 2007 210 3 732 739 2-s2.0-33846649566 10.1002/jcp.20895 (Pubitemid 46185042)
114. Li C.-W., Xia W., Huo L., Lim S.-O., Wu Y., Hsu J. L., Chao C.-H., Yamaguchi H., Yang N.-K., Ding Q., Wang Y., Lai Y.-J., LaBaff A. M., Wu T.-J., Lin B.-R., Yang M.-H., Hortobagyi G. N., Hung M.-C., Epithelial-mesenchymal transition induced by TNF- α requires NF- B-mediated transcriptional upregulation of Twist1. Cancer Research 2012 72 5 1290 1300 2-s2.0-84857734397 10.1158/0008-5472.CAN-11-3123
115. Glait-Santar C., Benayahu D., Regulation of SVEP1 gene expression by 17 β -estradiol and TNF α in pre-osteoblastic and mammary adenocarcinoma cells. Journal of Steroid Biochemistry and Molecular Biology 2012 130 1-2 36 44 2-s2.0-84859241655 10.1016/j.jsbmb.2011.12.015
116. Glait-Santar C., Pasmanik-Chor M., Benayahu D., Expression pattern of SVEP1 alternatively-spliced forms. Gene 2012 505 1 137 145
117. Gupta G. P., Massagué J., Cancer metastasis: building a framework. Cell 2006 127 4 679 695 2-s2.0-33751252276 10.1016/j.cell.2006.11.001 (Pubitemid 44781029)
118. Trachootham D., Alexandre J., Huang P., Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nature Reviews Drug Discovery 2009 8 7 579 591 2-s2.0-67650071137 10.1038/nrd2803
119. Nagano O., Okazaki S., Saya H., Redox regulation in stem-like cancer cells by CD44 variant isoforms. Oncogene 2013 10.1038/onc.2012.638
120. Lo M., Wang Y.-Z., Gout P. W., The xc- cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. Journal of Cellular Physiology 2008 215 3 593 602 2-s2.0-42949126711 10.1002/jcp.21366 (Pubitemid 351632680)
121. Yae T., Tsuchihashi K., Ishimoto T., Motohara T., Yoshikawa M., Yoshida G. J., Wada T., Masuko T., Mogushi K., Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nature Communications 2012 3 article 883
122. Ishimoto T., Nagano O., Yae T., Tamada M., Motohara T., Oshima H., Oshima M., Ikeda T., Asaba R., Yagi H., Masuko T., Shimizu T., Ishikawa T., Kai K., Takahashi E., Imamura Y., Baba Y., Ohmura M., Suematsu M., Baba H., Saya H., CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc- and thereby promotes tumor growth. Cancer Cell 2011 19 3 387 400 2-s2.0-79952528125 10.1016/j.ccr.2011.01.038
123. Yoshikawa M., Tsuchihashi K., Ishimoto T., Yae T., Motohara T., Sugihara E., Onishi N., Masuko T., Yoshizawa K., xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. Cancer Research 2013 73 6 1855 1866
124. Venables J. P., Brosseau J., Gadea G., Klinck R., Prinos P., Beaulieu J., Lapointe E., Durand M., Thibault P., RBFOX2 is an important regulator of mesenchymal tissue-specific splicing in both normal and cancer tissues. Molecular and Cellular Biology 2013 33 2 396 405
125. Misquitta-Ali C. M., Cheng E., O'Hanlon D., Liu N., McGlade C. J., Tsao M. S., Blencowe B. J., Global profiling and molecular characterization of alternative splicing events misregulated in lung cancer. Molecular and Cellular Biology 2011 31 1 138 150 2-s2.0-78751700506 10.1128/MCB.00709-10
126. Menon R., Omenn G. S., Identification of alternatively spliced transcripts using a proteomic informatics approach. Methods in Molecular Biology 2011 696 319 326 2-s2.0-79952196824
127. Klinck R., Bramard A., Inkel L., Dufresne-Martin G., Gervais-Bird J., Madden R., Paquet É. R., Koh C., Venables J. P., Prinos P., Jilaveanu-Pelmus M., Wellinger R., Rancourt C., Chabot B., Elela S. A., Multiple alternative splicing markers for ovarian cancer. Cancer Research 2008 68 3 657 663 2-s2.0-38849179519 10.1158/0008-5472.CAN-07-2580 (Pubitemid 351206740)
128. Bemmo A., Dias C., Rose A. A. N. R., Russo C., Siegel P., Majewski J., Exon-Level transcriptome profiling in murine breast cancer reveals splicing changes specific to tumors with different metastatic abilities. PLoS ONE 2010 5 8 2-s2.0-77957772409 10.1371/journal.pone.0011981 e11981
129. Shultz J. C., Goehe R. W., Wijesinghe D. S., Murudkar C., Hawkins A. J., Shay J. W., Minna J. D., Chalfant C. E., Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a. Cancer Research 2010 70 22 9185 9196 2-s2.0-78549234102 10.1158/0008-5472.CAN-10-1545
130. Sangodkar J., DiFeo A., Feld L., Bromberg R., Schwartz R., Huang F., Terzo E. A., Choudhri A., Narla G., Targeted reduction of KLF6-SV1 restores chemotherapy sensitivity in resistant lung adenocarcinoma. Lung Cancer 2009 66 3 292 297 2-s2.0-68949206913 10.1016/j.lungcan.2009.02.014
131. Wang J., Zhang J., Li K., Zhao W., Cui Q., SpliceDisease database: linking RNA splicing and disease. Nucleic Acids Research 2012 40 D1055 D1059
132. Bartel F., Schulz J., Böhnke A., Blümke K., Kappler M., Bache M., Schmidt H., Würl P., Taubert H., Hauptmann S., Significance of HDMX-S (or MDM4) mRNA splice variant overexpression and HDMX gene amplification on primary soft tissue sarcoma prognosis. International Journal of Cancer 2005 117 3 469 475 2-s2.0-26444599546 10.1002/ijc.21206 (Pubitemid 41429571)
133. Arvanitis D. A., Lianos E., Soulitzis N., Delakas D., Spandidos D. A., Deregulation of p73 isoform equilibrium in benign prostate hyperplasia and prostate cancer. Oncology Reports 2004 12 5 1131 1137 2-s2.0-16544383365
134. Shultz J. C., Goehe R. W., Murudkar C. S., Wijesinghe D. S., Mayton E. K., Massiello A., Hawkins A. J., Mukerjee P., Pinkerman R. L., Park M. A., Chalfant C. E., SRSF1 regulates the alternative splicing of caspase 9 via a novel intronic splicing enhancer affecting the chemotherapeutic sensitivity of non-small cell lung cancer cells. Molecular Cancer Research 2011 9 7 889 900 2-s2.0-79960681326 10.1158/1541-7786.MCR-11-0061
135. + hematopoietic progenitor cells and leukemic cells from CD95-mediated apoptosis. Oncogene 2005 24 14 2421 2429 2-s2.0-20144389573 10.1038/sj.onc.1208432 (Pubitemid 40546700)
136. Neklason D. W., Solomon C. H., Dalton A. L., Kuwada S. K., Burt R. W., Intron 4 mutation in APC gene results in splice defect and attenuated FAP phenotype. Familial Cancer 2004 3 1 35 40 2-s2.0-3142698784 10.1023/B:FAME. 0000026824.85766.22 (Pubitemid 40655352)
137. Okumura N., Yoshida H., Kitagishi Y., Nishimura Y., Matsuda S., Alternative splicings on p53, BRCA1 and PTEN genes involved in breast cancer. Biochemical and Biophysical Research Communications 2011 413 3 395 399 2-s2.0-80053377363 10.1016/j.bbrc.2011.08.098
138. Barron V. A., Lou H., Alternative splicing of the neurofibromatosis type I pre-mRNA. Bioscience Reports 2012 32 2 131 138 2-s2.0-84856921335 10.1042/BSR20110060
139. Hu Y., Fang C., Xu Y., The effect of isoforms of the cell polarity protein, human ASIP, on the cell cycle and Fas/FasL-mediated apoptosis in human hepatoma cells. Cellular and Molecular Life Sciences 2005 62 17 1974 1983 2-s2.0-24344444517 10.1007/s00018-005-5134-z (Pubitemid 41261844)
140. Takehara T., Liu X., Fujimoto J., Friedman S. L., Takahashi H., Expression and role of Bcl-xL in human hepatocellular carcinomas. Hepatology 2001 34 1 55 61 2-s2.0-0034950640 10.1053/jhep.2001.25387 (Pubitemid 32591483)
141. Line A., Slucka Z., Stengrevics A., Li G., Rees R. C., Altered splicing pattern of TACC1 mRNA in gastric cancer. Cancer Genetics and Cytogenetics 2002 139 1 78 83 2-s2.0-0036873739 10.1016/S0165-4608(02)00607-6 (Pubitemid 36120415)
142. Kotoula V., Barbanis S., Nikolakaki E., Koufoyannis D., Papadimitriou C. S., Karkavelas G., Relative expression of human telomerase catalytic subunit (hTERT) transcripts in astrocytic gliomas. Acta Neuropathologica 2004 107 5 443 451 2-s2.0-2342435109 10.1007/s00401-004-0832-4 (Pubitemid 38559254)
143. Wang X. Q., Luk J. M., Leung P. P., Wong B. W., Stanbridge E. J., Fan S. T., Alternative mRNA splicing of liver intestine-cadherin in hepatocellular carcinoma. Clinical Cancer Research 2005 11 2 483 489 2-s2.0-12244254020 (Pubitemid 40116870)
144. Cooper C., Guo J., Yan Y., Chooniedass-Kothari S., Hube F., Hamedani M. K., Murphy L. C., Myal Y., Leygue E., Increasing the relative expression of endogenous non-coding Steroid Receptor RNA Activator (SRA) in human breast cancer cells using modified oligonucleotides. Nucleic Acids Research 2009 37 13 4518 4531 2-s2.0-67949094334 10.1093/nar/gkp441
145. Shieh J.-J., Liu K.-T., Huang S.-W., Chen Y.-J., Hsieh T.-Y., Modification of alternative splicing of Mcl-1 pre-mRNA using antisense morpholino oligonucleotides induces apoptosis in basal cell carcinoma cells. Journal of Investigative Dermatology 2009 129 10 2497 2506 2-s2.0-70349160026 10.1038/jid.2009.83
146. Pankratova S., Nielsen B. N., Shiraishi T., Nielsen P. E., PNA-mediated modulation and redirection of Her-2 pre-mRNA splicing: specific skipping of erbB-2 exon 19 coding for the ATP catalytic domain. International Journal of Oncology 2010 36 1 29 38 2-s2.0-74549134760 10.3892/ijo-00000472
147. Lefave C. V., Squatrito M., Vorlova S., Rocco G. L., Brennan C. W., Holland E. C., Pan Y.-X., Cartegni L., Splicing factor hnRNPH drives an oncogenic splicing switch in gliomas. EMBO Journal 2011 30 19 4084 4097 2-s2.0-80053577349 10.1038/emboj.2011.259
148. Shultz J. C., Chalfant C. E., Caspase 9b: a new target for therapy in non-small-cell lung cancer. Expert Review of Anticancer Therapy 2011 11 4 499 502 2-s2.0-79955083536 10.1586/era.11.23
149. Goldberg M. S., Sharp P. A., Pyruvate kinase M2-specific siRNA induces apoptosis and tumor regression. Journal of Experimental Medicine 2012 209 2 217 224 2-s2.0-84856913587 10.1084/jem.20111487
150. Wang Z., Jeon H. Y., Rigo F., Bennett C. F., Krainer A. R., Manipulation of PK-M mutually exclusive alternative splicing by antisense oligonucleotides. Open Biology 2012 2 10 120133
151. Wong M. S., Chen L., Foster C., Kainthla R., Shay J. W., Wright W. E., Regulation of telomerase alternative splicing: a target for chemotherapy. Cell Reports 3 4 1028 1035 10.1016/j.celrep.2013.03.011 2013
152. Weidle U. H., Maisel D., Klostermann S., Weiss E. H., Schmitt M., Differential splicing generates new transmembrane receptor and extracellular matrix-related targets for antibody-based therapy of cancer. Cancer Genomics and Proteomics 2011 8 5 211 226 2-s2.0-80054678708
153. Okamoto I., Kenyon L. C., Emlet D. R., Mori T., Sasaki J.-I., Hirosako S., Ichikawa Y., Kishi H., Godwin A. K., Yoshioka M., Suga M., Matsumoto M., Wong A. J., Expression of constitutively activated EGFRvIII in non-small cell lung cancer. Cancer Science 2003 94 1 50 56 2-s2.0-0038324367 10.1111/j.1349-7006.2003.tb01351.x (Pubitemid 36575858)
154. Gridelli C., Maione P., Ferrara M. L., Rossi A., Cetuximab and other anti-epidermal growth factor receptor monoclonal antibodies in the treatment of non-small cell lung cancer. Oncologist 2009 14 6 601 611 2-s2.0-68049084773 10.1634/theoncologist.2008-0153
155. Scott A. M., Lee F.-T., Tebbutt N., Herbertson R., Gill S. S., Liu Z., Skrinos E., Murone C., Saunder T. H., Chappell B., Papenfuss A. T., Poon A. M. T., Hopkins W., Smyth F. E., MacGregor D., Cher L. M., Jungbluth A. A., Ritter G., Brechbiel M. W., Murphy R., Burgess A. W., Hoffman E. W., Johns T. G., Old L. J., A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors. Proceedings of the National Academy of Sciences of the United States of America 2007 104 40 4071 4076 2-s2.0-35648970071 10.1073/pnas.0611693104 (Pubitemid 47181580)
156. Klausz K., Berger S., Lammerts van Bueren J. J., Derer S., Lohse S., Dechant M., van de Winkel J. G. J., Peipp M., Parren P. W. H. I., Valerius T., Complement-mediated tumor-specific cell lysis by antibody combinations targeting epidermal growth factor receptor (EGFR) and its variant III (EGFRvIII). Cancer Science 2011 102 10 1761 1768 2-s2.0-80053386362 10.1111/j.1349-7006.2011.02019. x
157. Wang H., Zhou M., Shi B., Zhang Q., Jiang H., Sun Y., Liu J., Zhou K., Yao M., Gu J., Yang S., Mao Y., Li Z., Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity. Neoplasia 2011 13 5 461 471 2-s2.0-79955865397 10.1593/neo.101744
158. Wang H., Shi B., Zhang Q., Jiang H., Hu S., Kong J., Yao M., Yang S., Li Z., Growth and metastasis suppression of glioma xenografts expressing exon 4-deletion variant of epidermal growth factor receptor by monoclonal antibody CH12-mediated receptor degradation. FASEB Journal 2012 26 1 73 80 2-s2.0-84855408587 10.1096/fj.11-191064
159. Seiter S., Tilgen W., Herrmann K., Schadendorf D., Patzelt E., Möller P., Zöller M., Expression of CD44 splice variants in human skin and epidermal tumours. Virchows Archiv 1996 428 3 141 149 2-s2.0-0029967271 (Pubitemid 26237444)
160. Mack B., Gires O., CD44s and CD44v6 expression in head and neck epithelia. PLoS ONE 2008 3 10 2-s2.0-54449085703 10.1371/journal.pone.0003360 e3360
161. Riechelmann H., Sauter A., Golze W., Hanft G., Schroen C., Hoermann K., Erhardt T., Gronau S., Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncology 2008 44 9 823 829 2-s2.0-50049134725 10.1016/j.oraloncology.2007.10.009
162. Börjesson P. K. E., Postema E. J., Roos J. C., Colnot D. R., Marres H. A. M., Van Schie M. H., Stehle G., De Bree R., Snow G. B., Oyen W. J. G., Van Dongen G. A. M. S., Phase I therapy study with 186Re-labeled humanized monoclonal antibody BIWA 4 (Bivatuzumab) in patients with head and neck squamous cell carcinoma. Clinical Cancer Research 2003 9 10 2-s2.0-10844290511
163. Masuko K., Okazaki S., Satoh M., Tanaka G., Ikeda T., Torii R., Ueda E., Nakano T., Danbayashi M., Tsuruoka T., Ohno Y., Yagi H., Yabe N., Yoshida H., Tahara T., Kataoka S., Oshino T., Shindo T., Niwa S.-I., Ishimoto T., Baba H., Hashimoto Y., Saya H., Masuko T., Anti-tumor effect against human cancer xenografts by a fully human monoclonal antibody to a variant 8-epitope of CD44R1 expressed on cancer stem cells. PLoS ONE 2012 7 1 2-s2.0-84855829724 10.1371/journal.pone.0029728 e29728
164. Carmeliet P., Angiogenesis in life, disease and medicine. Nature 2005 438 7070 932 936 2-s2.0-30744479430 10.1038/nature04478 (Pubitemid 43093958)
165. Castellani P., Viale g. V. G., Dorcaratto A., Nicolo G., Kaczarek J., Querze G., Zardi L., The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. International Journal of Cancer 1994 59 5 612 618 2-s2.0-0028116528 10.1002/ijc.2910590507 (Pubitemid 24358583)
166. Ventura E., Sassi F., Parodi A., Balza E., Borsi L., Castellani P., Carnemolla B., Zardi L., Alternative splicing of the angiogenesis associated extra-domain B of fibronectin regulates the accessibility of the B-C loop of the type III repeat 8. PLoS ONE 2010 5 2 2-s2.0-77949344954 10.1371/journal.pone. 0009145 e9145
167. Czabanka M., Parmaksiz G., Bayerl S. H., Nieminen M., Trachsel E., Menssen H. D., Erber R., Neri D., Vajkoczy P., Microvascular biodistribution of L19-SIP in angiogenesis targeting strategies. European Journal of Cancer 2011 47 8 1276 1284 2-s2.0-79955536635 10.1016/j.ejca.2011.02.001
168. Webb T. R., Joyner A. S., Potter P. M., The development and application of small molecule modulators of SF3b as therapeutic agents for cancer. Drug Discovery Today 2013 18 1-2 43 49
169. Bonnal S., Vigevani L., Valcárcel J., The spliceosome as a target of novel antitumour drugs. Nature Reviews 2012 11 11 847 859
170. Corrionero A., Miñana B., Valcárcel J., Reduced fidelity of branch point recognition and alternative splicing induced by the anti-tumor drug spliceostatin A. Genes and Development 2011 25 5 445 459 2-s2.0-79952220808 10.1101/gad.2014311
171. O'Brien K., Matlin A. J., Lowell A. M., Moore M. J., The biflavonoid isoginkgetin is a general inhibitor of pre-mRNA splicing. Journal of Biological Chemistry 2008 283 48 33147 33154 2-s2.0-57749093482 10.1074/jbc.M805556200
172. Muraki M., Ohkawara B., Hosoya T., Onogi H., Koizumi J., Koizumi T., Sumi K., Yomoda J.-I., Murray M. V., Kimura H., Furuichi K., Shibuya H., Krainer A. R., Suzuki M., Hagiwara M., Manipulation of alternative splicing by a newly developed inhibitor of Clks. Journal of Biological Chemistry 2004 279 23 24246 24254 2-s2.0-2342655502 10.1074/jbc.M314298200 (Pubitemid 38725286)
173. Allende-Vega N., Dayal S., Agarwala U., Sparks A., Bourdon J.-C., Saville M. K., p53 is activated in response to disruption of the pre-mRNA splicing machinery. Oncogene 2012 32 1 14 2-s2.0-84857008283 10.1038/onc.2012.38
174. Amin E. M., Oltean S., Hua J., Gammons M. V. R., Hamdollah-Zadeh M., Welsh G. I., Cheung M.-K., Ni L., Kase S., Rennel E. S., Symonds K. E., Nowak D. G., Royer-Pokora B., Saleem M. A., Hagiwara M., Schumacher V. A., Harper S. J., Hinton D. R., Bates D. O., Ladomery M. R., WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell 2011 20 6 768 780 2-s2.0-83455263848 10.1016/j.ccr.2011.10.016
175. Soret J., Bakkour N., Maire S., Durand S., Zekri L., Gabut M., Fic W., Divita G., Rivalle C., Dauzonne D., Nguyen C. H., Jeanteur P., Tazi J., Selective modification of alternative splicing by indole derivatives that target serine-arginine-rich protein splicing factors. Proceedings of the National Academy of Sciences of the United States of America 2005 102 24 8764 8769 2-s2.0-20844442133 10.1073/pnas.0409829102 (Pubitemid 40862809)
176. Ghigna C., De Toledo M., Bonomi S., Valacca C., Gallo S., Apicella M., Eperon I., Tazi J., Biamonti G., Pro-metastatic splicing of Ron proto-oncogene mRNA can be reversed: therapeutic potential of bifunctional oligonucleotides and indole derivatives. RNA Biology 2010 7 4 495 503 2-s2.0-77957302252 10.4161/rna.7.4.12744
177. Lai F., Jiang C. C., Farrelly M. L., Zhang X. D., Hersey P., Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors. Melanoma Research 2012 22 3 244 251 2-s2.0-84859870180 10.1097/CMR.0b013e328353eff2
178. Jiang C. C., Lai F., Tay K. H., Croft A., Rizos H., Becker T. M., Yang F., Liu H., Thorne R. F., Hersey P., Zhang X. D., Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS. Cell Death and Disease 2010 1 9, article e69 2-s2.0-79951818357 10.1038/cddis.2010.48
179. Muntoni F., Wood M. J. A., Targeting RNA to treat neuromuscular disease. Nature Reviews Drug Discovery 2011 10 8 621 637 2-s2.0-79960981599 10.1038/nrd3459
180. Havens M. A., Duelli D. M., Hastings M. L., Targeting RNA splicing for disease therapy. Wiley Interdisciplinary Reviews 2013 4 3 247 266
181. Bauman J. A., Li S.-D., Yang A., Huang L., Kole R., Anti-tumor activity of splice-switching oligonucleotides. Nucleic Acids Research 2010 38 22 8348 8356 2-s2.0-78650440393 10.1093/nar/gkq731
182. Liu R., Page C., Beidler D. R., Wicha M. S., Núñez G., Overexpression of Bcl-X(L) promotes chemotherapy resistance of mammary tumors in a syngeneic mouse model. American Journal of Pathology 1999 155 6 1861 1867 2-s2.0-0032763060
183. Xu G., Zhang C., Zhang J., Dominant negative STAT3 suppresses the growth and invasion capability of human lung cancer cells. Molecular Medicine Reports 2009 2 5 819 824 2-s2.0-69249203685 10.3892/mmr-00000178
184. Zammarchi F., De Stanchina E., Bournazou E., Supakorndej T., Martires K., Riedel E., Corben A. D., Bromberg J. F., Cartegni L., Antitumorigenic potential of STAT3 alternative splicing modulation. Proceedings of the National Academy of Sciences of the United States of America 2011 108 43 17779 17784 2-s2.0-80055072546 10.1073/pnas.1108482108
185. Vorlová S., Rocco G., LeFave C. V., Jodelka F. M., Hess K., Hastings M. L., Henke E., Cartegni L., Induction of antagonistic soluble decoy receptor tyrosine kinases by intronic poly A activation. Molecular Cell 2011 43 6 927 939 2-s2.0-80052999677 10.1016/j.molcel.2011.08.009
186. Bauman J. A., Kole R., Modulation of RNA splicing as a potential treatment for cancer. Bioengineered Bugs 2011 2 3 125 128 2-s2.0-79960282729 10.4161/bbug.2.3.15165
187. Skordis L. A., Dunckley M. G., Yue B., Eperon I. C., Muntoni F., Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proceedings of the National Academy of Sciences of the United States of America 2003 100 7 4114 4119 2-s2.0-0037388256 10.1073/pnas.0633863100 (Pubitemid 36418166)
188. Elbashir S. M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T., Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001 411 6836 494 498 2-s2.0-0035942736 10.1038/35078107 (Pubitemid 32494397)
189. Camacho-Vanegas O., Narla G., Teixeira M. S., DiFeo A., Misra A., Singh G., Chan A. M., Friedman S. L., Feuerstein B. G., Martignetti J. A., Functional inactivation of the KLF6 tumor suppressor gene by loss of heterozygosity and increased alternative splicing in glioblastoma. International Journal of Cancer 2007 121 6 1390 1395 2-s2.0-34548066569 10.1002/ijc.22809 (Pubitemid 47293811)
190. DiFeo A., Feld L., Rodriguez E., Wang C., Beer D. G., Martignetti J. A., Narla G., A functional role for KLF6-SV1 in lung adenocarcinoma prognosis and chemotherapy response. Cancer Research 2008 68 4 965 970 2-s2.0-39449090999 10.1158/0008-5472.CAN-07-2604 (Pubitemid 351272212)
191. Massiello A., Chalfant C. E., SRp30a (ASF/SF2) regulates the alternative splicing of caspase-9 pre-mRNA and is required for ceramide-responsiveness. Journal of Lipid Research 2006 47 5 892 897 2-s2.0-33646792573 10.1194/jlr.C600003-JLR200 (Pubitemid 43764686)
192. Goehe R. W., Shultz J. C., Murudkar C., Usanovic S., Lamour N. F., Massey D. H., Zhang L., Camidge D. R., Shay J. W., Minna J. D., Chalfant C. E., hnRNP L regulates the tumorigenic capacity of lung cancer xenografts in mice via caspase-9 pre-mRNA processing. Journal of Clinical Investigation 2010 120 11 3923 3939 2-s2.0-78049448047 10.1172/JCI43552
193. Devi G. R., Beer T. M., Corless C. L., Arora V., Weller D. L., Iversen P. L., In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. Clinical Cancer Research 2005 11 10 3930 3938 2-s2.0-18844429452 10.1158/1078-0432.CCR- 04-2091 (Pubitemid 40685615)
194. Altieri D. C., Survivin, cancer networks and pathway-directed drug discovery. Nature Reviews Cancer 2008 8 1 61 70 2-s2.0-37549036729 10.1038/nrc2293
195. Altieri D. C., Validating survivin as a cancer therapeutic target. Nature Reviews Cancer 2003 3 1 46 54 2-s2.0-0037267333 10.1038/nrc968 (Pubitemid 37328886)
196. Carrasco R. A., Stamm N. B., Marcusson E., Sandusky G., Iversen P., Patel B. K. R., Antisense inhibition of survivin expression as a cancer therapeutic. Molecular Cancer Therapeutics 2011 10 2 221 232 2-s2.0-79951821796 10.1158/1535-7163.MCT-10-0756
197. Talbot D. C., Ranson M., Davies J., Lahn M., Callies S., André V., Kadam S., Burgess M., Slapak C., Olsen A. L., McHugh P. J., De Bono J. S., Matthews J., Saleem A., Price P., Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study. Clinical Cancer Research 2010 16 24 6150 6158 2-s2.0-78650335854 10.1158/1078-0432.CCR-10-1932